BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with ATO, differentially increased the basal phosphorylation of Y360 BCR in Ba/F3p210T315I, K562-R and LAMA84-R cell lines and in four out of the five primary-derived leukemic samples and Y177 BCR in Ba/F3p210T315I cell line and CML#1 and CML#3 patient-derived primary samples.